Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan.
Ronna Hauser, PharmD
Advertisement
Articles by Ronna Hauser, PharmD
Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discusses concerns about the implementation of the MDPNP.
A recent analysis from NCPA showed potential weekly cash flow shortfalls for pharmacies and annual revenue losses.
Advertisement
Latest Updated Articles
“We’ve Got to Get This Right From the Start”: Expert Discusses MDPNP Impacts on PharmaciesPublished: April 23rd 2025 | Updated:
NCPA Report Outlines Potential Negative Impacts of MDPNP, SolutionsPublished: April 21st 2025 | Updated:
NCPA Raises Concerns About Implementation of Medicare Drug Price Negotiation ProgramPublished: April 17th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
3
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
4
PCV20 Demonstrates Real-World Effectiveness Against Pneumonia in Older Adults
5
